Trial Profile
NETTLE Study: NeuroEndocrine Tumour Therapy with Lutetium-177 octreotate and Everolimus. A Phase I/II study of Everolimus in combination with Lutetium-177 octreotate for the treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Capecitabine; Everolimus; Temozolomide
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms NETTLE
- 01 Aug 2015 Status changed from not yet recruiting to recruiting, according to results published in the Cancer Biotherapy and Radiopharmaceuticals.
- 02 Mar 2011 New trial record